Payload Information
General Information of This Payload
| Payload ID | PAY0VMDIF |
|||||
|---|---|---|---|---|---|---|
| Name | IG-L-70 Payload |
|||||
| Synonyms |
IG-L-70 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C45H49N5O4 |
|||||
| Isosmiles | O=C1C2=C(CN1[C@@H](CCC3=O)C(N3)=O)C=C(N4CCN(CC4)CC5CCN(C6=CC=C([C@@H]([C@H]7C8=CC=CC=C8)C9=C(CC7)C=C(O)C=C9)C=C6)CC5)C=C2 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C45H49N5O4/c51-37-12-15-39-33(27-37)8-13-38(31-4-2-1-3-5-31)43(39)32-6-9-35(10-7-32)48-20-18-30(19-21-48)28-47-22-24-49(25-23-47)36-11-14-40-34(26-36)29-50(45(40)54)41-16-17-42(52)46-44(41)53/h1-7,9-12,14-15,26-27,30,38,41,43,51H,8,13,16-25,28-29H2,(H,46,52,53)/t38-,41+,43+/m1/s1
|
|||||
| InChIKey |
TZZDVPMABRWKIZ-XMOGEVODSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
723.918 |
Polar area |
96.43 |
||
Complexity |
1990.969069 |
xlogp Value |
6.0537 |
|||
Heavy Count |
54 |
Rot Bonds |
7 |
|||
Hbond acc |
7 |
Hbond Donor |
2 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Tumor Growth Inhibition (TGI) | 105 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 108 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 113 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 124 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 131 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 47 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 65 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 77 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 78 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 85 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 87 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | <=89 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 94 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 95 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 97 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 98 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Degradation Concentration (DC50) | 0.4 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Effective Concentration (EC50) | 1 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Degradation Concentration (DC50) | 1.8 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Degradation Concentration (DC50) | 2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Effective Concentration (EC50) | 2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed |
Each Antibody-drug Conjugate Related to This Payload